Clene to Present at Upcoming Investor Conferences
Clene Inc. (NASDAQ: CLNN) will participate in several upcoming investor conferences, showcasing its commitment to revolutionizing the treatment of neurodegenerative diseases.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clene Inc. (NASDAQ: CLNN) will participate in several upcoming investor conferences, showcasing its commitment to revolutionizing the treatment of neurodegenerative diseases. The company will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 2 p.m. ET, followed by participation in the Benchmark Healthcare House Call Virtual 1x1 Conference on June 2, 2022, and the JMP Securities Life Sciences Conference on June 15, 2022, also at 2 p.m. ET. Clene focuses on addressing energetic failure, a key factor in many neurological conditions.
Details
News Market Reaction – CLNN
The recorded move for CLNN in the trading session of this news was +1.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, May 16, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will participate in the following investor conferences:
- H.C. Wainwright Global Investment Conference, May 24-26, 2022
Presentation Time: May 25, 2022, at 2 p.m. ET
- Benchmark Healthcare House Call Virtual 1x1 Conference, June 2, 2022
- JMP Securities Life Sciences Conference, June 15-16, 2022
Presentation Time: June 15, 2022, at 2 p.m. ET
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
Media Contact
Erica Fiorini, Ph.D., or David Schull
Russo Partners, LLC
Erica.fiorini@russopartnersllc.com
David.schull@russopartnersllc.com
+1-212-845-4253
Investor Contact
John Woolford
Managing Director, Westwicke
clene@westwicke.com
+1-443-213-0506
Source: Clene Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.